All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Checkpoint inhibitors
Checkpoint inhibitors
Checkpoint inhibitors target molecules responsible for the regulation of the immune response. The expression of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, suppresses T cell activation. In response to a normal immune challenge, this pathway prevents hyperstimulation, and in malignancy this can halt immune responses against the tumor, enabling unimpeded progression.
Save to your areas of interest